Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M McNeil

Showing results (311-320 of 331) with videos related to

Pageof 34
Sort By:
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 21, 2006
c-Myc overexpression and endocrine resistance in breast cancerCatriona M McNeil, C Marcelo Sergio, Luke R Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2018
The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease OutcomeCarmela Ricciardelli, Tina Bianco-Miotto, Shalini Jindal, et al.
MMWR. Morbidity and Mortality Weekly Report|January 6, 2022
Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth - Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021Heather S Lipkind, Gabriela Vazquez-Benitez, Malini DeSilva, et al.
JAMA|March 19, 1997
A coccidioidomycosis outbreak following the Northridge, Calif, earthquakeE Schneider, R A Hajjeh, R A Spiegel, et al.
Oncogene|March 17, 2009
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcomeE K A Millar, J L Dean, C M McNeil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Histopathology|May 13, 2010
High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtypeSarah J Zardawi, Ibrahim Zardawi, Catriona M McNeil, et al.
International Journal of Cancer|August 14, 2009
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative statusNiamh C Murphy, Andrew V Biankin, Ewan K A Millar, et al.
JAMA Network Open|April 8, 2024
Attitudes Toward COVID-19 Vaccines Among Pregnant and Recently Pregnant IndividualsJoshua T B Williams, Kate Kurlandsky, Kristin Breslin, et al.
Pageof 34

Showing results (311-320 of 331) with videos related to

Sort By:
Pageof 34
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 21, 2006
c-Myc overexpression and endocrine resistance in breast cancerCatriona M McNeil, C Marcelo Sergio, Luke R Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2018
The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease OutcomeCarmela Ricciardelli, Tina Bianco-Miotto, Shalini Jindal, et al.
MMWR. Morbidity and Mortality Weekly Report|January 6, 2022
Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth - Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021Heather S Lipkind, Gabriela Vazquez-Benitez, Malini DeSilva, et al.
JAMA|March 19, 1997
A coccidioidomycosis outbreak following the Northridge, Calif, earthquakeE Schneider, R A Hajjeh, R A Spiegel, et al.
Oncogene|March 17, 2009
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcomeE K A Millar, J L Dean, C M McNeil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Histopathology|May 13, 2010
High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtypeSarah J Zardawi, Ibrahim Zardawi, Catriona M McNeil, et al.
International Journal of Cancer|August 14, 2009
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative statusNiamh C Murphy, Andrew V Biankin, Ewan K A Millar, et al.
JAMA Network Open|April 8, 2024
Attitudes Toward COVID-19 Vaccines Among Pregnant and Recently Pregnant IndividualsJoshua T B Williams, Kate Kurlandsky, Kristin Breslin, et al.
Pageof 34